Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RPT193 · 1 trial · 1 indication
Number of participants with abnormal laboratory values and/or adverse events that are related to treatment
| Arm | Type | Description |
|---|---|---|
| COMPLETED ENROLLMENT -- Single Dose Escalation Part A - active | EXPERIMENTAL | Increasing doses of RPT193 will be administered to healthy volunteers |
| COMPLETED ENROLLMENT -- Single Dose Escalation Part A - placebo | PLACEBO_COMPARATOR | Matching placebo will be administered to healthy volunteers |
| COMPLETED ENROLLMENT -- Multiple Dose Escalation Part B - active | EXPERIMENTAL | Increasing doses of RPT193 will be administered once/day for 7 days to healthy volunteers |
| COMPLETED ENROLLMENT -- Multiple Dose Escalation Part B - placebo | PLACEBO_COMPARATOR | Matching placebo will be administered once/day for 7 days to healthy volunteers |
| COMPLETED ENROLLMENT -- Expansion Part C - active | EXPERIMENTAL | RPT193 will be administered daily for 28 days to patients with atopic dermatitis |
| COMPLETED ENROLLMENT -- Expansion Part C - placebo | PLACEBO_COMPARATOR | Matching placebo will be administered daily for 28 days to patients with atopic dermatitis |
| Name | Type | Description |
|---|---|---|
| RPT193 | DRUG | Antagonist of the CCR4 chemokine receptor |
| Placebo | DRUG | Matching placebo |
Selected Inclusion Criteria: Parts A \& B (COMPLETED ENROLLMENT): * Healthy male or female * 18-55 years of age, inclusive * At least 50 kg in weight * BMI: 18.0-30.0 kg/m2, inclusive Part C (COMPLETED ENROLLMENT): * Male or female with atopic dermatitis * 18-65 years of age, inclusive * BMI bet...
Top 20 of 25 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 5 | PHASE3 | Lebrikizumab, Corticosteroid |
| AbbVie, Inc. | ABBV | 10 | PHASE3 | Upadacitinib, corticosteroids |
| Pfizer Inc. | PFE | 12 | PHASE3 | Abrocitinib |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | Dupilumab |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib, Vehicle |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof , 1%, Vehicle |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Sunshine Biopharma Incorporated | SBFM | 3 | PHASE3 | 611, corticosteroid |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-914 |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Arcutis Biotherapeutics Inc | ARQT | 1 | PHASE1 | ARQ-234 |
RPT193 is an investigational small molecule being developed for the treatment of atopic dermatitis, a form of eczema. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied in patients with atopic dermatitis to evaluate its safety and potential efficacy.
RPT193 is a small molecule, but its specific molecular target has not been disclosed in available information. The drug is being investigated for its effects in atopic dermatitis, a condition driven by inflammatory pathways, though the exact mechanism of action remains undisclosed.
RPT193 is being developed by RAPT Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol RAPT. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with atopic dermatitis.
RPT193 is in Phase 1 clinical development. It has completed a first-in-human study that included healthy volunteers and patients with atopic dermatitis. The drug is still investigational and has not received regulatory approval for any use.
RPT193 has one completed clinical trial, identified as NCT04271514, titled 'A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis.' This Phase 1 study enrolled 103 participants in the United States and Netherlands and was placebo-controlled, randomized, and double-blind.
No alternative names for RPT193 have been reported. The drug is known solely by its investigational identifier RPT193 and is being developed by RAPT Therapeutics. It is a distinct small molecule candidate in clinical development for atopic dermatitis.